MetaCap

Natera Inc. (NTRA)

NASDAQ: NTRAHealth CareMedical SpecialitiesUSD

273.40-16.52 (-5.70%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NTRA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$39.64B
EPS (TTM)
-$1.12
52-week range
181.00 – 437.41
Day range
271.85 – 288.41
Volume / Avg
1.38M / 1.77M
Beta
—

52-week range

$181.00$437.41

NTRA stock today

Natera (NTRA) closed at $273.40 on Nov 20, down 5.70% (-$16.52), versus the S&P 500's 3.70% decline. Shares are 37.5% below their 52-week high of $437.41, set on Oct 6, 2026 and 51.0% above the 52-week low of $181.00, in the middle of the past year's range. NTRA is up 19.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 18.5%.

Natera has posted a net loss over the last twelve months (EPS of -$1.12), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Natera

Company profile

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions.

Industry
Medical Specialities
CEO
Mr. Steven Leonard Chapman
Headquarters
Austin, TX
Employees
6,135
IPO year
2015
Website
natera.com

Financial highlights

Full financials

In fiscal 2025, Natera generated $2.31 billion in revenue, up 35.9% from fiscal 2024, its 8th consecutive year of revenue growth. Natera reported a net loss of $208.2 million, compared with a loss of $190.4 million a year earlier. Operating margin was -13.4%.

Natera annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$2.31B$1.70B$1.08B$820.22M$625.49M
Growth+35.90%+56.75%+31.99%+31.13%+59.97%
Net income$-208.16M$-190.43M$-434.80M$-547.80M$-471.72M
EPS (diluted)$-1.52$-1.53$-3.78$-5.57$-5.21

Analyst forecast

Forecast

Consensus (22 analysts)

strong_buy

Avg. price target

$410.26+50.06%

  • Strong buy 4
  • Buy 16
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $280.00High $500.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.42 vs $-0.17
Surprise
-147.06%

NTRA news

All NTRA news

Natera peers

Health Care sector
NTRA peer companies
CompanyPrice% ChgMarket capCompare
HUMHumana Inc.390.00+2.63%$46.84Bvs NTRA
CNCCentene Corporation63.78-2.74%$31.58Bvs NTRA
LHLabcorp Holdings Inc.367.13-0.47%$29.81Bvs NTRA
ILMNIllumina Inc.192.82-3.90%$29.15Bvs NTRA
DGXQuest Diagnostics Incorporated258.28-0.31%$28.42Bvs NTRA
GHGuardant Health Inc.145.83+0.16%$19.73Bvs NTRA
MOHMolina Healthcare Inc198.39-2.43%$10.36Bvs NTRA
HSICHenry Schein Inc.83.52-1.51%$9.23Bvs NTRA

Indexes, lists and sector

Natera stock FAQ

What is Natera's stock price today?

NTRA last traded at $273.40 as of Nov 20, 4:00 PM EST, down 5.70% on the day. Prices are delayed at least 15 minutes.

Who is Natera's CEO?

Mr. Steven Leonard Chapman is the chief executive officer of Natera Inc., which has about 6,135 employees.

What is the NTRA 52-week high?

The 52-week high for NTRA is $437.41 and the 52-week low is $181.00. The stock is currently 37.5% below its high.

Compare NTRA